With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.30459-17-7,1-(4-Trifluoromethylphenyl)piperazine,as a common compound, the synthetic route is as follows.
A solution of Intermediate?A? (200 mg, 0.55 mmol), l-[4-(trifluoromethyl)- phenyl | piperazine (381 mg, 1.65 mmol), and Et3N (170 mg, 1.68 mmol) in CH2CI2 (5 mL) was stirred for 16 h at rt, then extracted with 2×20 mL of CH2CI2. The combined organic layers were concentrated under vacuum and purified with silica gel column chromatography using EtOAc / hexane (1:2) to afford 260 mg (98%) of the title compound as an off-white solid. LC-MS: (ES, m/z): 481
30459-17-7, As the paragraph descriping shows that 30459-17-7 is playing an increasingly important role.
Reference：
Patent; CENTAURUS THERAPEUTICS; ROMERO, Donna, L.; BLITZER, Jeremy; (242 pag.)WO2019/140188; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics